Wedbush raised the firm’s price target on Kiniksa (KNSA) to $44 from $38 and keeps an Outperform rating on the shares. The firm says the company heads into Q3 earnings on the heels of another strong quarter that further reinforced Arcalyst’s durable growth trajectory in recurrent pericarditis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: